Literature DB >> 9009345

Protection against infection in mice vaccinated with a Brucella abortus mutant.

M L Boschiroli1, S L Cravero, A I Arese, E Campos, O L Rossetti.   

Abstract

This study determines whether a genetically engineered mutant of Brucella abortus, strain M-1, possesses differences in protective properties compared to the parental strain, vaccine S19. M-1 is a mutant unable to express BP26, a periplasmic protein with potential use in diagnosis. Mice vaccinated with S19 developed antibodies against BP26, while those vaccinated with M-1 did not. However, mice vaccinated with S19 or M-1 were similarly protected against challenge with pathogenic strain 2308, suggesting that the lack of BP26 does not affect the induction of the protective immune response exerted by S19. These and previous results showing that bacterial invasion and growth or replication in mouse spleens were indistinguishable between strains M-1 and S19 could indicate that the mutant is an attenuated strain which maintains the same protective properties as S19.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9009345      PMCID: PMC176128          DOI: 10.1128/iai.65.2.798-800.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Immunological response to the Brucella abortus GroEL homolog.

Authors:  J Lin; L G Adams; T A Ficht
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

2.  Brucella abortus deficient in copper/zinc superoxide dismutase is virulent in BALB/c mice.

Authors:  E Latimer; J Simmers; N Sriranganathan; R M Roop; G G Schurig; S M Boyle
Journal:  Microb Pathog       Date:  1992-02       Impact factor: 3.738

3.  Antigens of Brucella abortus S19 immunodominant for bovine lymphocytes as identified by one- and two-dimensional cellular immunoblotting.

Authors:  B M Brooks-Worrell; G A Splitter
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus.

Authors:  L N Araya; P H Elzer; G E Rowe; F M Enright; A J Winter
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

5.  Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308.

Authors:  M G Stevens; S C Olsen; G W Pugh; M V Palmer
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51.

Authors:  M G Stevens; S C Olsen; G W Pugh; D Brees
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Deletion of the BCSP31 gene of Brucella abortus by replacement.

Authors:  S M Halling; P G Detilleux; F M Tatum; B A Judge; J E Mayfield
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  Biological properties of RB51; a stable rough strain of Brucella abortus.

Authors:  G G Schurig; R M Roop; T Bagchi; S Boyle; D Buhrman; N Sriranganathan
Journal:  Vet Microbiol       Date:  1991-07       Impact factor: 3.293

9.  Immune responses and protection against infection and abortion in cattle experimentally vaccinated with mutant strains of Brucella abortus.

Authors:  N F Cheville; M G Stevens; A E Jensen; F M Tatum; S M Halling
Journal:  Am J Vet Res       Date:  1993-10       Impact factor: 1.156

10.  Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis.

Authors:  M P Jiménez de Bagüés; P H Elzer; S M Jones; J M Blasco; F M Enright; G G Schurig; A J Winter
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

View more
  9 in total

1.  Use of recombinant BP26 protein in serological diagnosis of Brucella melitensis infection in sheep.

Authors:  A Cloeckaert; S Baucheron; N Vizcaino; M S Zygmunt
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

2.  Selection of protective epitopes for Brucella melitensis by DNA vaccination.

Authors:  Xinghong Yang; Mary Hudson; Nancy Walters; Robert F Bargatze; David W Pascual
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

Review 3.  Brucellosis: the case for live, attenuated vaccines.

Authors:  Thomas A Ficht; Melissa M Kahl-McDonagh; Angela M Arenas-Gamboa; Allison C Rice-Ficht
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

4.  Epitope mapping of the Brucella melitensis BP26 immunogenic protein: usefulness for diagnosis of sheep brucellosis.

Authors:  Patricia Seco-Mediavilla; Jean-Michel Verger; Maggy Grayon; Axel Cloeckaert; Clara M Marín; Michel S Zygmunt; Luis Fernández-Lago; Nieves Vizcaíno
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

5.  O-Polysaccharide epitopic heterogeneity at the surface of Brucella spp. studied by enzyme-linked immunosorbent assay and flow cytometry.

Authors:  A Cloeckaert; V Weynants; J Godfroid; J M Verger; M Grayon; M S Zygmunt
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

6.  Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice.

Authors:  A Tibor; I Jacques; L Guilloteau; J M Verger; M Grayon; V Wansard; J J Letesson
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

7.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

8.  Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M.

Authors:  Mina J Izadjoo; Apurba K Bhattacharjee; Chrysanthi M Paranavitana; Ted L Hadfield; David L Hoover
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

9.  Brucella abortus S19 GFP-tagged vaccine allows the serological identification of vaccinated cattle.

Authors:  Carlos Chacón-Díaz; Ana Zabalza-Baranguá; Beatriz San Román; José-María Blasco; Maite Iriarte; Dariana Salas-Alfaro; Gabriela Hernández-Mora; Elías Barquero-Calvo; Caterina Guzmán-Verri; Esteban Chaves-Olarte; María-Jesús Grilló; Edgardo Moreno
Journal:  PLoS One       Date:  2021-11-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.